BioNTech and Pfizer are working on new vaccines

The German company BioNTech has announced that it will start vaccine trials against new variants of COVID-19 with the US firm Pfizer.

It is reported that clinical trials will begin this month. We are talking about variants BA.4 and BA.5 of the "omicron" strain of coronavirus. If the tests are successful, the production of the vaccine will begin in October.

But it requires a license. The company's vaccines against the BA.1 variant, released in the spring, were not approved by American and European regulators.